Lodie Naimeh, MD
Payments from drug & device makers
Across 280 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Sanofi$992
- Johnson & Johnson$740
- CSL Behring$425
- AbbVie$392
- Novartis$385
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,12299%
- Education$881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $1,033 |
| Sanofi | 53 | $992 |
| Johnson & Johnson | 7 | $740 |
| CSL Behring | 27 | $425 |
| AbbVie(2 entities) | 4 | $392 |
| Novartis | 17 | $385 |
| Regeneron Healthcare Solutions, Inc. | 16 | $342 |
| GSK | 20 | $324 |
| Teva Pharmaceuticals USA, Inc. | 5 | $279 |
| Corium, LLC | 2 | $217 |
| Genentech USA, Inc. | 12 | $207 |
| Pharming Healthcare, Inc. | 7 | $171 |
| Amgen | 8 | $161 |
| Kaleo, Inc. | 10 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $134 |
| Optinose US, Inc. | 6 | $133 |
| Otsuka America Pharmaceutical, Inc. | 1 | $124 |
| Pfizer | 6 | $121 |
| Alk-abello, Inc | 6 | $120 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $119 |
| Axsome Therapeutics, Inc. | 1 | $108 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Organon | 6 | $60 |
| Shire North American Group Inc | 3 | $57 |
| Blueprint Medicines Corporation | 3 | $52 |
| Greer Laboratories, Inc. | 3 | $41 |
| Boehringer Ingelheim | 2 | $38 |
| Galderma Laboratories, L.p. | 2 | $38 |
| Hikma Pharmaceuticals USA | 2 | $37 |
| Mylan Specialty L.p. | 1 | $24 |
| Biocryst US Sales Co., LLC | 1 | $21 |
| LEO Pharma Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $20 |
| Merck | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| GC Biopharma USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$383
- VRAYLAR$371
- BEVESPI AEROSPHERE$364
- TEZSPIRE$364
- FASENRA$364
- INVEGA SUSTENNA$227
- REXULTI$124
- AUSTEDO$122
- UZEDY$122
- Azstarys$121
- Auvelity$108
- INVEGA TRINZA$103
How this compares
Too few allergy providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 23 | $101,272 |
| TezspireTezepelumab-Ekko | 13 | $53,365 |
| Dupixent SyringeDupilumab | 13 | $47,759 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $22,801 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $11,861 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $10,829 |
| Spiriva RespimatTiotropium Bromide | 19 | $9,662 |
| Arnuity ElliptaFluticasone Furoate | 31 | $8,434 |
| Epinephrine | 22 | $3,834 |
| Montelukast Sodium | 124 | $2,154 |
| AsmanexMometasone Furoate | 11 | $1,338 |
| Omeprazole | 58 | $927 |
| Azelastine Hcl | 27 | $859 |
| Fluticasone Propionate | 48 | $798 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire | $1,033 | $53,36513 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $324 | $43,09582 claims |
| Boehringer IngelheimSpiriva Respimat | $38 | $9,66219 claims |
| Hikma Pharmaceuticals USAEpinephrine | $37 | $3,83422 claims |
| MerckAsmanex | $19 | $1,33811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other allergy in Tulsa
- Timothy NickelTulsa$51K
- Jane PurserTulsa$16K
- James LoveTulsa$7K
- Martha TarpayOklahoma City$6.3M
- Claire AtkinsonOklahoma City$9K
- Gregory MetzOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.